Thus, in the past decade, EGFR inhibition with tyrosine kinase inhibitors (TKI)s remarkably changed the treatment paradigm of NSCLC patients with EGFR driver mutations [4,5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.